Halia Therapeutics Completes Enrollment in Phase 2a Clinical Trial of HT-6184 for Myelodysplastic Syndrome (MDS)

LEHI, Utah, June 4, 2025 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering therapies inspired by genetic resilience, today announced the completion of enrollment for its open-label Phase 2a clinical trial evaluating HT-6184 (Ofirnoflast) in patients with lower-risk Myelodysplastic Syndrome (MDS) who are refractory to, intolerant of, or ineligible for erythropoiesis-stimulating agents (ESA).

The study (CTRI/2023/11/059758) is designed to evaluate the efficacy, safety, and biomarker response of HT-6184, a novel allosteric modulator of NEK7 that disrupts NEK7–NLRP3 protein interaction, thereby preventing the formation of the NLRP3 inflammasome. This mechanism also promotes the disassembly of pre-formed NLRP3 inflammasomes, targeting a key inflammatory pathway implicated in bone marrow dysfunction in myelodysplastic syndromes (MDS). The two-stage study enrolled 18 evaluable patients in Stage 1 and has now completed enrollment of an additional 15 participants in Stage 2.

"Completing enrollment in our Phase 2a MDS study is a major milestone as we continue to validate our mechanism of action targeting innate immune dysregulation," said Dr. David Bearss, CEO of Halia Therapeutics. "This study provides important proof-of-concept data to support the therapeutic potential of HT-6184 in reducing clonal inflammation and improving hematologic outcomes for patients with symptomatic anemia."

The trial consists of a 16-week treatment period, followed by a response-based continuation phase. Responders may continue on therapy, while non-responders showing a greater than 30% reduction in variant allele frequency (VAF) clone size may receive up to 16 additional weeks of treatment, either as monotherapy or in combination with prior ESA therapy. Key study objectives include evaluating efficacy through hematological improvement, clonal suppression, and VAF reduction, assessing safety and patient tolerance, monitoring changes in inflammasome-related biomarkers, and measuring quality of life using patient-reported outcome tools.

An interim analysis was conducted following Stage 1, and topline results from the complete study are expected later this year.

About Halia Therapeutics
Halia Therapeutics is redefining treatment paradigms by targeting the innate immune system and harnessing genetic resilience. Founded on breakthrough research identifying protective mutations in individuals genetically predisposed to severe diseases, Halia's therapies aim to restore immune balance in inflammatory and neurodegenerative conditions.

The company's pipeline includes:

• HT-6184, currently in a Phase 2a trial for Myelodysplastic Syndrome (MDS)
• HT-6184, in combination with semaglutide, a planned Phase 2a trial in obese and Type 2 diabetes (T2D) patients, is expected to initiate in 3Q25.
• HT-4253, a neuroinflammation-targeted candidate, is currently in an ongoing Phase 1 clinical trial (NCT06537817), expected to conclude in 3Q25.

For more information about Ofirnoflast (HT-6184), HT-4253, or ongoing clinical trials, please visit www.haliatx.com.

Media Contact

Taylor Avei
Director of Business Development
Halia Therapeutics
info@haliatx.com 

Photo - https://mma.prnewswire.com/media/2702932/Halia_Therapeutics_Logo.jpg